Cognitive Behavioural Therapy for Insomnia and Healthy Ageing

Key Takeaways

Cognitive behavioural therapy for insomnia (CBT-I) is a structured, multicomponent treatment that targets behaviours and beliefs that perpetuate chronic insomnia; sleep hygiene alone is not equivalent to CBT-I. [1]
In older adults, trials and meta-analyses consistently show improvement in insomnia severity, time awake during the night, time taken to fall asleep, and sleep efficiency. Total sleep time may change little or can initially decrease. [2] [3]
One large trial found fewer episodes of major depression over three years after CBT-I than after sleep education, while smaller trials report changes in fatigue and selected inflammatory markers. These outcomes do not establish slower biological ageing. [7] [8] [10]
Evidence that CBT-I prevents dementia, cardiovascular disease, disability, or premature death is not established. A recent trial found no improvement in cognition or beta-amyloid deposition over one year. [9]

CBT-I treats persistent insomnia as a pattern maintained by conditioned wakefulness, irregular sleep opportunity, and unhelpful expectations or worry about sleep. It combines behavioural and cognitive methods rather than trying only to increase time in bed or provide general advice about sleep. [1] [3]

Who This Is Useful For

This page is for readers assessing whether treating chronic insomnia has relevance to healthy ageing. It separates direct evidence about insomnia and daytime symptoms from secondary evidence about mood and biomarkers, and from unproven claims about dementia prevention or longer life. [2] [7] [9]

What CBT-I Contains

Multicomponent CBT-I commonly includes stimulus control, a structured adjustment of time in bed, cognitive therapy, relaxation methods, and sleep education. Stimulus control rebuilds the association between bed and sleep; adjusting time in bed consolidates sleep opportunity; cognitive work examines beliefs and predictions that sustain arousal. The components and their sequencing vary across protocols. [1] [3]

The American Academy of Sleep Medicine strongly supports multicomponent CBT-I for chronic insomnia in adults but gives only conditional support to several components used alone. It also suggests against sleep hygiene as a stand-alone treatment, an important distinction when interpreting studies described simply as “sleep education.” [1]

Evidence at a Glance

Outcome	Main Finding	Interpretation	Main Limitation
Insomnia and sleep continuity	Older-adult trials show lower insomnia severity and less wakefulness before and after sleep onset, with higher sleep efficiency. [2] [5]	Supports a direct treatment effect on chronic insomnia. [2]	Many outcomes are derived from diaries, and participants cannot be blinded to behavioural treatment. [2]
Fatigue, pain, and daily symptoms	Telephone CBT-I improved fatigue for 12 months in older adults with osteoarthritis; a small pain benefit was not sustained. [10]	Some daytime effects can extend beyond the sleep measures. [10]	Results from a comorbid osteoarthritis sample may not generalize to all older adults. [10]
Major depression	A 291-person trial found lower incidence and recurrence over 36 months after CBT-I than after sleep education. [7]	Provides a specific preventive signal for late-life depression among adults with insomnia. [7]	This was one single-site trial in adults without current depression or recent major illness. [7]
Inflammatory markers	A 123-person trial reported reductions in C-reactive protein and selected cellular or gene-expression measures. [8]	Supports a possible biological pathway rather than a clinical healthy-ageing outcome. [8]	Markers and time points did not respond uniformly, and the trial was not powered for disease events. [8]
Cognition and dementia-related biology	A 200-person trial found no between-group improvement in cognitive domains or beta-amyloid deposition over one year. [9]	Does not support a near-term cognitive or amyloid effect. [9]	Beta-amyloid was measured in a smaller subsample, and one year is short relative to dementia development. [9]

Sleep Outcomes in Older Adults

A meta-analysis of 14 studies in older adults estimated an 8.36-percentage-point increase in diary-based sleep efficiency, about 9 minutes less time to fall asleep, and about 23 minutes less wakefulness after sleep onset. The pooled estimate for total sleep time was about 12 minutes shorter, illustrating that more consolidated sleep need not mean more time asleep during the treatment period. Heterogeneity was substantial across these outcomes. [2]

Individual trials support the same general pattern. A four-week group programme improved sleep timing, wakefulness after sleep onset, sleep efficiency, fatigue, and dysfunctional beliefs in 118 adults with sleep-maintenance insomnia. A smaller trial comparing CBT-I, zopiclone, and placebo found sustained improvements in sleep efficiency and night-time wakefulness with CBT-I at six months, although its sample of 46 limits precision and generalizability. [5] [4]

Mood and Depression

In a randomized trial of 291 adults aged 60 years or older who had insomnia but not current major depression, two months of CBT-I was compared with sleep education. Over 36 months, incident or recurrent major depression occurred less often in the CBT-I group, and sustained remission of insomnia was associated with lower depression risk. This is stronger evidence than an observational association, but replication across settings and populations is still important. [7]

Improvement in depressive symptoms within an insomnia trial and prevention of a diagnosed depressive episode are different endpoints. The late-life insomnia trial provides evidence for the latter in its selected population; it does not show that CBT-I prevents every psychiatric or neurological consequence associated with poor sleep. [6] [7]

Inflammation and Other Biological Pathways

In 123 older adults with insomnia, CBT-I was compared with tai chi and a sleep-education control. Relative to education, CBT-I reduced C-reactive protein at selected follow-ups, short-term stimulated monocyte cytokine production, and pro-inflammatory gene expression. The pattern varied by marker and time point, so the study supports biological responsiveness more clearly than a broad anti-inflammatory effect. [8]

Biomarker change is not interchangeable with prevention of cardiovascular disease, frailty, dementia, or death. Those clinical endpoints require trials designed with adequate sample size and follow-up; they were not outcomes established by this biomarker study. [8]

Cognition, Dementia, and Longevity

A recent randomized trial assigned 200 cognitively normal older adults with insomnia symptoms to CBT-I or a control condition. At one year it found no between-group differences in information-processing speed, executive function, memory, or beta-amyloid deposition; amyloid imaging was available in a subsample of 50. The result narrows claims about short-term cognitive and amyloid effects but cannot determine dementia incidence over many years. [9]

No cited CBT-I trial establishes longer lifespan or reduced all-cause mortality. The healthy-ageing relevance is therefore clearest at the level of treating insomnia and selected related symptoms, with promising but incomplete evidence for some downstream pathways and outcomes. [2] [7] [8] [9]

Delivery Format and Access

CBT-I is not limited to weekly in-person individual sessions. In 327 adults aged 60 years or older with insomnia and osteoarthritis pain, six telephone sessions produced greater improvement in insomnia and fatigue than education, with sleep differences maintained at 12 months. A 2025 trial in 311 adults aged 55 to 95 also found that a tailored digital programme improved insomnia outcomes through 12 months compared with online education. [10] [11]

These studies show that structured content can be delivered through different channels. They do not imply that every app, self-help resource, or abbreviated programme contains equivalent components, support, adherence monitoring, or evidence. The digital trial also reported investigator financial relationships with the company holding relevant programme intellectual property, which is material when interpreting implementation claims. [1] [11]

Evidence Quality and Interpretation

Confidence is high that multicomponent CBT-I improves chronic insomnia in adults, and moderate that the benefit extends to older populations and several delivery formats. Consistency across guidelines, meta-analyses, and randomized trials supports this conclusion despite heterogeneity and unavoidable lack of participant blinding. [1] [2] [3] [10]

Confidence is lower for broader healthy-ageing outcomes. Depression prevention is supported by one substantial long-term trial, and inflammatory findings come from smaller biomarker studies. Evidence is currently insufficient for dementia prevention, reduced cardiovascular events, reduced disability, or life extension. [7] [8] [9]

What This Does Not Mean

It does not mean normal age-related changes in sleep timing or duration are themselves insomnia disorder. CBT-I trials enrol people with defined symptoms or diagnoses. [1] [2]
It does not mean more time in bed is the mechanism of benefit; consolidation of sleep opportunity is a central behavioural element, and total sleep time may initially fall. [2] [3]
It does not mean improved sleep efficiency demonstrates slower biological ageing or longer life. [8] [9]
It does not mean sleep hygiene advice, a relaxation recording, and full multicomponent CBT-I are interchangeable interventions. [1]

Practical Interpretation Examples

If sleep efficiency rises while total sleep time changes little: this can represent less wakefulness within a similar or shorter sleep opportunity, which is consistent with CBT-I trial outcomes. [2] [3]
If a trial reports lower C-reactive protein: this is an intermediate biological finding, not direct evidence of fewer age-related diseases or deaths. [8]
If a programme is labelled digital CBT-I: compare its components, comparator, support, completion, follow-up, and conflicts of interest with the tested protocol. [1] [11]

References

Edinger, J. D., et al. (2021). Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine. https://pubmed.ncbi.nlm.nih.gov/33164742/
Huang, K., et al. (2022). Efficacy of cognitive behavioral therapy for insomnia (CBT-I) in older adults with insomnia: a systematic review and meta-analysis. Australasian Psychiatry. https://pubmed.ncbi.nlm.nih.gov/35968818/
Trauer, J. M., et al. (2015). Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Annals of Internal Medicine. https://pubmed.ncbi.nlm.nih.gov/26054060/
Sivertsen, B., et al. (2006). Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA. https://pubmed.ncbi.nlm.nih.gov/16804151/
Lovato, N., et al. (2014). Evaluation of a brief treatment program of cognitive behavior therapy for insomnia in older adults. Sleep. https://pubmed.ncbi.nlm.nih.gov/24470701/
Irwin, M. R., et al. (2014). Cognitive behavioral therapy vs. Tai Chi for late life insomnia and inflammatory risk: a randomized controlled comparative efficacy trial. Sleep. https://pubmed.ncbi.nlm.nih.gov/25142571/
Irwin, M. R., et al. (2022). Prevention of incident and recurrent major depression in older adults with insomnia: a randomized clinical trial. JAMA Psychiatry. https://pubmed.ncbi.nlm.nih.gov/34817561/
Irwin, M. R., et al. (2015). Cognitive behavioral therapy and tai chi reverse cellular and genomic markers of inflammation in late-life insomnia: a randomized controlled trial. Biological Psychiatry. https://pubmed.ncbi.nlm.nih.gov/25748580/
Siengsukon, C. F., et al. (2026). The impact of cognitive behavioral therapy for insomnia on cognitive performance and amyloid beta in older adults: a randomized controlled trial. Alzheimer's & Dementia. https://pubmed.ncbi.nlm.nih.gov/42298279/
McCurry, S. M., et al. (2021). Effect of telephone cognitive behavioral therapy for insomnia in older adults with osteoarthritis pain: a randomized clinical trial. JAMA Internal Medicine. https://pubmed.ncbi.nlm.nih.gov/33616613/
Ritterband, L. M., et al. (2025). A randomized controlled trial of a digital cognitive behavioral therapy for insomnia for older adults. npj Digital Medicine. https://pubmed.ncbi.nlm.nih.gov/40681664/

Educational Disclaimer

This page summarizes population and clinical-trial evidence and does not provide a diagnosis, treatment recommendation, or individualized medical advice. Persistent sleep difficulty can have multiple causes, and the content and suitability of behavioural treatment depend on clinical context.